Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Akdeniz University | OTHER |
Not provided
Not provided
The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more. At least 90% of new cases can be reduced with proper treatment and monitoring of the eyes. The longer a person has diabetes, the more likely it is to develop diabetic retinopathy. Each year in the United States, diabetic retinopathy accounts for 12% of all new cases of blindness. It is also the leading cause of blindness in people between the ages of 20 and 64. The most important complication of diabetes leading to vision loss is diabetic retinopathy. Depending on this, macular edema, bleeding into the retina and vitreous,neovascular glaucoma can cause blindness.
Diabetic retinopathy (DR) is a leading cause of vision-loss globally. Of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one third of DR is vision-threatening DR, including diabetic macular edema (DME). Diabetic retinopathy is a retinal disease that can often be stopped with early diagnosis, but if neglected, it can lead to severe vision loss, including permanent blindness. Diabetes has high morbidity and there are millions of people who should be screened for diabetic retinopathy (DR). Annual eye screening is recommended for all diabetic patients since vision loss can be prevented if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is less than that needed to screen a growing diabetic population. Therefore, the automatic DR screening system will be able to screen more diabetic patients and diagnose them early.
EyeCheckup is an automated retinal screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DR. This study is designed to assess the safety and efficacy of EyeCheckup.
The study is a single center study to determine the sensitivity and specificity of EyeCheckup to diabetic retinopathy. EyeCheckup is an automated software device that is designed to analyze ocular fundus digital color photographs taken in frontline primary care settings in order to quickly screen for diabetic retinopathy (DR).
This is a prospective study to assess the safety and efficacy of EyeCheckup in screening for DR.
This study was carried out in a single center at Akdeniz University Faculty of Medicine with primary endpoints to determine the sensitivity and specificity of EyeCheckup to diabetic retinopathy in the primary care setting.
Methods and tools to be used in the study:
Clinical and laboratory tests to be performed:
After exclusions, this study will enroll up to 900 subjects who are diagnosed with diabetes by the endocrinology polyclinic and meet the eligibility criteria. Participants who meet the eligibility criteria will be recruited after obtaining written informed consent from primary health care providers. Subjects will undergo fundus photography per, Food and Drug Administration (FDA) cleared, ophthalmic cameras (product code: HKI). Images will be taken according to a specific EyeCheckup imaging protocol provided to the ophthalmic camera operator and then analyzed by the EyeCheckup device.
The photography protocol consists of two images of the ocular fundus (one optic disc nerve centered, one macula centered), obtained from both eyes of enrolled participants.
After the retinal images taken from ophthalmic cameras (product code: HKI), images are analyzed with EyeCheckup and a scan report is prepared. If it is necessary to enlarge the pupils, eye enlarging eye drops are applied and wait 15-30 minutes. This information is noted. DR is diagnosed by examination by a retina specialist with the captured images. EyeCheckup success rate is calculated by comparing both reports.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Color Fundus Photography | Procedure | Subjects will undergo fundus photography before and after administration of mydriatic agent. | ||
| Mydriatic Agent | Drug | Subjects will be administered mydriatic medication to dilate their pupils. |
| |
| EyeCheckup - AI Based DR Screening | Device | Screening for existence of "More than mild" or "Vision-threatening" Diabetic Retinopathy, and/or Diabetic Macular Edema. |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity(mtmDR) | Sensitivity for detecting more than mild diabetic retinopathy | 1 visit (1 day) |
| Sensitivity(vtDR) | Sensitivity for detecting vision threatening diabetic retinopathy | 1 visit (1 day) |
| Specificity(mtmDR) | Specificity for detecting more than mild diabetic retinopathy | 1 visit (1 day) |
| Specificity(vtDR) | Specificity for detecting vision threatening diabetic retinopathy | 1 visit (1 day) |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnosability | percentage of patients with image quality sufficient for EyeCheckup to produce an output to patients with image quality sufficient for the clinical reference standard to produce an output | 1 Day |
| Non-Dilated EyeCheckup Usage |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Primary care clinic - invitation to volunteer,
Diabetic Patients
Eighteen years of age or older
Have been referred to an ophthalmologist for eye examination to screen for diabetic retinopathy
Diseases Polyclinic with the diagnosis of diabetes and were able to view the posterior polar region of the eye with an ophthalmic camera.
900 volunteer patients who applied to the Akdeniz University Endocrinology and Metabolic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| A Burak Bilgin, Assoc. Prof. | Instructor, Retinal Surgeon, Academic Advisor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Akdeniz University Hospital | Antalya | 07070 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41541002 | Derived | Aydemir M, Bilgin AB, Sari R, Dogan ME, Bulut M, Akar Y. Assessment of Correlation Between Diabetic Retinopathy and Metabolic Biomarkers Using Artificial Intelligence. J Diabetes Res. 2026 Jan 14;2026:9085827. doi: 10.1155/jdr/9085827. eCollection 2026. | |
| 38467864 | Derived | Dogan ME, Bilgin AB, Sari R, Bulut M, Akar Y, Aydemir M. Head to head comparison of diagnostic performance of three non-mydriatic cameras for diabetic retinopathy screening with artificial intelligence. Eye (Lond). 2024 Jun;38(9):1694-1701. doi: 10.1038/s41433-024-03000-9. Epub 2024 Mar 11. |
Not provided
Not provided
No individual data will be shared.
Not provided
Not provided
Not provided
Not provided
Participants were evaluated for media opacity and other retinal diseases that might prevent good retinal photography.
Participants were reffered to by the Endocrionlogy Department at Akdeniz University Hosptital for an ophthalmic examitation to the opthalmology department to screen for diabetic retinopathy, where they were invited to participate in the study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Screening Population | Prospective Study Participants |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 5, 2021 |
Not provided
Not provided
Not provided
Not provided
Percentage of participants for whom Non-Dilated Images were sufficient to use EyeCheckup
| 1 Day |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Number of Enrolled Adult Diabetic Participants
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Screening Population | Prospective Study Participants |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
| |||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Sensitivity(mtmDR) | Sensitivity for detecting more than mild diabetic retinopathy | Posted | Number | 95% Confidence Interval | percentage of true positives | 1 visit (1 day) |
|
|
| ||||||||||||||||||||||||||||||||
| Primary | Sensitivity(vtDR) | Sensitivity for detecting vision threatening diabetic retinopathy | Posted | Number | 95% Confidence Interval | percentage of true positives | 1 visit (1 day) |
|
| |||||||||||||||||||||||||||||||||
| Primary | Specificity(mtmDR) | Specificity for detecting more than mild diabetic retinopathy | Posted | Number | 95% Confidence Interval | percentage of true negatives | 1 visit (1 day) |
|
| |||||||||||||||||||||||||||||||||
| Primary | Specificity(vtDR) | Specificity for detecting vision threatening diabetic retinopathy | Posted | Number | 95% Confidence Interval | percentage of true negatives | 1 visit (1 day) |
|
| |||||||||||||||||||||||||||||||||
| Secondary | Diagnosability | percentage of patients with image quality sufficient for EyeCheckup to produce an output to patients with image quality sufficient for the clinical reference standard to produce an output | Posted | Number | 95% Confidence Interval | percentage of participants | 1 Day |
|
| |||||||||||||||||||||||||||||||||
| Secondary | Non-Dilated EyeCheckup Usage | Percentage of participants for whom Non-Dilated Images were sufficient to use EyeCheckup | Posted | Number | 95% Confidence Interval | percentage of patients imaged undilated | 1 Day |
|
|
patient was seen only once for a signle day for retinal imaging throughout the study, therefore 1 day
The images used in our study do not pose any risk or harm to the patients.Only fundus images of the patients will be evaluated.
The study is expected to pose minimal risk to both camera operators and participants, as the camera systems used have been previously approved by the FDA for ocular fundus photography, and tropicamide 1% eye drops for pupil dilation is an FDA-approved drug product and have been shown to have minimal side effects.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Prospective Study Participants | Screening Population at Primary Care | 0 | 865 | 0 | 865 | 0 | 865 |
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Prof.Dr. Ahmet Burak Bilgin | Akdeniz University | 5465473336 | gozdrburakbilgin@gmail.com |
| Mar 23, 2023 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D003930 | Diabetic Retinopathy |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D009184 | Mydriatics |
| ID | Term |
|---|---|
| D001337 | Autonomic Agents |
| D018373 | Peripheral Nervous System Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided
|
|
|
|
|